DIAMEDICA THERAPEUTICS INC (DMAC) Forecast, Price Target & Analyst Ratings
NASDAQ:DMAC • CA25253X2077
7.91 USD
+0.2 (+2.59%)
Last: Mar 4, 2026, 01:56 PM
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for DIAMEDICA THERAPEUTICS INC (DMAC).
Forecast Snapshot
Consensus Price Target
$15.81
+ 99.87% Upside
Next Earnings Forecast
Release DateMar 16, 2026
PeriodQ4 / 2025
EPS Estimate-$0.18
Revenue Estimate
ChartMill Buy Consensus
81.82%
Weighted Analyst Rating Score
Price Target Details & History
Consensus Price Target and Range
Mean target
$15.81
Upside
+ 99.87%
From current price of $7.91 to mean target of $15.81, Based on 11 analyst forecasts
Low
$11.11
Median
$13.26
High
$26.25
Price Target Revisions
1 Month
0.00%
3 Months
25.68%
Price Target Summary
11 analysts have analysed DMAC and the average price target is 15.81 USD. This implies a price increase of 99.87% is expected in the next year compared to the current price of 7.91.
The average price target has been revised upward by 25.68% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
81.82%
DMAC was analyzed by 11 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about DMAC.
In the previous month the buy percentage consensus was at a similar level.
DMAC was analyzed by 11 analysts, which is quite many. So the average rating should be quite meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2025-11-14 | Cantor Fitzgerald | Initiate | Overweight |
| 2025-08-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-07-18 | Lake Street | Maintains | Buy -> Buy |
| 2025-07-18 | Craig-Hallum | Maintains | Buy -> Buy |
| 2025-07-18 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-05-29 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-19 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-10-07 | HC Wainwright & Co. | Initiate | Buy |
| 2024-08-16 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2024-03-21 | Craig-Hallum | Maintains | Buy -> Buy |
| 2023-06-22 | Oppenheimer | Upgrade | Perform -> Outperform |
| 2022-07-07 | Lake Street | Maintains | Buy |
| 2022-07-07 | Oppenheimer | Downgrade | Outperform -> Perform |
| 2022-07-07 | Craig-Hallum | Maintains | Buy |
| 2021-06-30 | Roth Capital | Maintains | Buy |
| 2021-04-08 | Oppenheimer | Initiate | Outperform |
| 2021-02-17 | Roth Capital | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
Release DateMar 16, 2026
PeriodQ4 / 2025
EPS Estimate-$0.18
Revenue Estimate
Revenue Q2QN/A
EPS Q2Q-2.00%
Number of Analysts6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
0.00%
EPS (3 Months)
0.00%
Next Earnings Summary
DMAC is expected to report earnings on 3/16/2026. The consensus EPS estimate for the next earnings is -0.18 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 500K | -100.00% | 3.79M | 14.304M 277.41% | 41.321M 188.88% | 122.07M 195.42% | 274.14M 124.58% | 465.77M 69.90% | 680.79M 46.16% | ||||||||||
| EBITDA YoY % growth | -2.479M -71.90% | -4.515M -82.11% | -6.746M -49.41% | -11.233M -71.54% | -11.016M -9.56% | N/A -7.45% | N/A -2.60% | -21.216M -51.95% | -26.622M -25.45% | -36.618M -37.44% | -45.594M -24.51% | -48.042M -5.37% | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -2.482M -71.52% | -4.519M -82.11% | -6.761M -49.61% | -12.09M -71.47% | -12.107M -9.54% | -15.531M -7.46% | -14.069M -2.60% | -21.46M -51.90% | -26.539M -25.46% | -35.457M -32.89% | -43.7M -23.25% | -58.565M -34.01% | -63.553M -8.52% | -53.713M 15.48% | -32.143M 40.16% | 64.083M 299.37% | 213.93M 233.83% | 389.86M 82.24% | |
| Operating Margin | N/A | N/A | -1,352.20% | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -1,545.25% | -444.30% | -129.99% | -26.33% | 23.38% | 45.93% | 57.27% | |
| EPS YoY % growth | N/A | N/A | N/A | -0.95 -9.07% | -0.74 12.36% | -0.74 17.95% | -0.53 18.75% | -0.62 -19.23% | -0.60 3.23% | -0.70 -16.28% | -0.77 -10.53% | -0.90 -16.40% | -0.91 -1.14% | -0.68 24.72% | -0.32 53.73% | 0.84 365.58% | 2.31 175.32% | 3.90 68.82% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 25 | Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.18 -2.00% | -0.20 -9.55% | -0.21 -17.11% | -0.22 -30.00% | -0.23 -25.93% | -0.18 6.89% | -0.18 12.90% | -0.18 16.92% | -0.18 20.59% |
| Revenue Q2Q % growth | |||||||||
| EBITDA Q2Q % growth | -10.302M -22.94% | -10.914M -34.19% | -10.914M -36.54% | -11.934M -32.59% | -11.934M -15.84% | -12.036M -10.28% | -12.036M -10.28% | -12.036M -0.85% | -12.036M -0.85% |
| EBIT Q2Q % growth | -9.747M -15.77% | -10.342M -26.99% | -10.587M -32.22% | -11.536M -27.71% | -12.016M -23.28% | -12.036M -16.38% | -12.036M -13.69% | -12.036M -4.33% | -12.036M -0.17% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
-14.37%
EPS Next 5 Year
-2.64%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
-21.87%
EBIT Next 5 Year
N/A
DIAMEDICA THERAPEUTICS INC / DMAC Forecast FAQ
What is the average price target for DIAMEDICA THERAPEUTICS INC (DMAC) stock?
11 analysts have analysed DMAC and the average price target is 15.81 USD. This implies a price increase of 99.87% is expected in the next year compared to the current price of 7.91.
When does DIAMEDICA THERAPEUTICS INC (DMAC) report earnings?
DIAMEDICA THERAPEUTICS INC (DMAC) will report earnings on 2026-03-16, after the market close.
What are the consensus estimates for DMAC stock next earnings?
The consensus EPS estimate for the next earnings of DIAMEDICA THERAPEUTICS INC (DMAC) is -0.18 USD and the consensus revenue estimate is 0 USD.
What is the consensus rating for DMAC stock?
The consensus rating for DIAMEDICA THERAPEUTICS INC (DMAC) is 81.8182 / 100 . This indicates that analysts generally have a positive outlook on the stock.